Sansure Biotech Inc. (SHA:688289)

Market Cap	8.16B -29.6%
Revenue (ttm)	1.60B +3.9%
Net Income	156.94M -45.2%
EPS	0.26 -46.3%
Shares Out	574.86M
PE Ratio	54.00
Forward PE	32.50
Dividend	0.52 (3.65%)
Ex-Dividend Date	Jun 22, 2026

Volume	1,450,973
Open	14.10
Previous Close	14.19
Day's Range	14.06 - 14.41
52-Week Range	13.85 - 23.45
Beta	0.51
Analysts	Strong Buy
Price Target	22.02 (+52.81%)
Earnings Date	Aug 28, 2026

About Sansure Biotech

Sansure Biotech Inc. researches and develops, produces, and sells in vitro diagnostic reagents and instruments in China and internationally. It offers nucleic acid and multiple nucleic acid diagnostic kits for coronavirus, CoV-2, influenza virus, and respiratory syncytial virus; DNA fluorescence and nucleic acid diagnostic kits for respiratory tract infections, HPV infections, and reproductive tract infections; nucleic acid tests and fluorescence diagnostic kits for blood-borne infections; RNA diagnostic kits for gastrointestinal infections; an...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 2008
• Employees: 2,128
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688289

Financial Performance

In 2025, Sansure Biotech's revenue was 1.64 billion, an increase of 12.58% compared to the previous year's 1.46 billion. Earnings were 198.94 million, a decrease of -27.82%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 18, 2026

Data Sources Report a data error